Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Blier

Showing results (211-220 of 229) with videos related to

Pageof 23
Sort By:
The Journal of Clinical Psychiatry|May 16, 2019
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant TreatmentRaoul Belzeaux, Laura M Fiori, Juan Pablo Lopez, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 24, 2025
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in DepressionBenjamin Schwartzmann, Prabhjot Dhami, Raaj Chatterjee, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Translational Psychiatry|October 10, 2019
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressantsChelsey Ju, Laura M Fiori, Raoul Belzeaux, et al.
Translational Psychiatry|October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression studyBenjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pharmacopsychiatry|June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 StudyFarhana Islam, Amanda Lisoway, Edward S Oh, et al.
Innovations in Clinical Neuroscience|February 1, 2021
THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND TrialAnthony L Vaccarino, Amir H Kalali, Pierre Blier, et al.
Pageof 23

Showing results (211-220 of 229) with videos related to

Sort By:
Pageof 23
The Journal of Clinical Psychiatry|May 16, 2019
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant TreatmentRaoul Belzeaux, Laura M Fiori, Juan Pablo Lopez, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 24, 2025
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in DepressionBenjamin Schwartzmann, Prabhjot Dhami, Raaj Chatterjee, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Translational Psychiatry|October 10, 2019
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressantsChelsey Ju, Laura M Fiori, Raoul Belzeaux, et al.
Translational Psychiatry|October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression studyBenjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Elife|July 11, 2023
<i>SNORD90</i> induces glutamatergic signaling following treatment with monoaminergic antidepressantsRixing Lin, Aron Kos, Juan Pablo Lopez, et al.
Pharmacopsychiatry|June 25, 2024
Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 StudyFarhana Islam, Amanda Lisoway, Edward S Oh, et al.
Innovations in Clinical Neuroscience|February 1, 2021
THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND TrialAnthony L Vaccarino, Amir H Kalali, Pierre Blier, et al.
Pageof 23